ArticleJACC. Case reports2025
Systematic Echocardiographic Screening Protocol for Cardiac Amyloidosis Detection: A Low-Cost, High-Impact Innovation.
Article in JACC. Case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Automated machine learning of echocardiographic strain enables identification of early myocardial changes in pre-symptomatic TTR carriers.medRxiv : the preprint server for health sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCardiac amyloidosis remains critically underdiagnosed, with a median diagnostic time of 2 years, as official echocardiographic reports generally fail to identify high-risk patients. PROJECT RATIONALE: We aimed to identify workflow barriers in patients undergoing echocardiographic assessment, including inconsistent strain imaging application and absence of standardized screening criteria for cardiac amyloidosis at the point of image acquisition. PROJECT SUMMARY: A systematic screening protocol was implemented for early identification of patients at risk for cardiac amyloidosis. We targeted patients ≥65 years (≥60 years for African Americans) with an interventricular septal wall thickness of ≥1.2 cm. Five innovations were implemented: daily technologist-driven screening, educational interventions, holographic visual aids, standardized strain imaging, and structured communication pathways. Among 82 patients screened over 7 months, 48.8% were classified as high risk, with most confirmed cases emerging from this tier. A total of 8 patients demonstrated positive or equivocal pyrophosphate scans, 2 had positive cardiac magnetic resonance imaging, and 2 had a positive biopsy, leading to 6 patients (7.3%) with confirmed cardiac amyloidosis after comprehensive work-up. Notably, 69.5% were identified during noncardiac admissions, where screening would typically be overlooked based on historical data. The protocol increased referrals and achieved meaningful diagnostic yield compared with near-zero detection at baseline. TAKE-HOME MESSAGE: Systematic screening with technologist empowerment and visual reminders dramatically improves cardiac amyloidosis detection, with most cases identified during incidental imaging that would otherwise be missed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.